Loading...
Loading...
VERA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | -1.0M |
| Gross Profit | 1.0M |
| Operating Expense | 32.1M |
| Operating I/L | -31.1M |
| Other Income/Expense | 2.7M |
| Interest Income | 4.2M |
| Pretax | -28.4M |
| Income Tax Expense | -1.0M |
| Net Income/Loss | -28.4M |
Vera Therapeutics, Inc. is a clinical stage biotechnology company in the United States, specializing in developing and commercializing treatments for serious immunological diseases. The company's lead product candidate, atacicept, is a fusion protein administered via subcutaneous injection and is currently in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. Additionally, Vera Therapeutics is developing MAU868, a monoclonal antibody for the treatment of BK viremia infections, which is in Phase 2 clinical trial. These innovative therapies form the core of the company's revenue generation strategy.
